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ABSTRACT 
Considering the therapeutic values of bioflavonoids in colon cancer treatment, six 2′-hydroxy chalcones (C1-C6) 
were synthesized, characterized and screened for in vitro cytotoxicity on human colon carcinoma (HCT116) and 
African green monkey kidney epithelial cells (Vero). Only C5 showed selective cytotoxicity against HCT116 cells. 
Other potent cytotoxic compounds were C1, C2 and C3. Further screening included enzyme inhibition studies on 
histone deacetylase (HDAC) enzyme where C1 showed lowest IC50 value (105.03 µM). Based on cytotoxicity data 
C1, C2 and C3 were selected for further in vitro mechanistic studies, namely apoptotic studies (Acridine or-
ange/Ethidium bromide (AO/EB) and Annexin V), cell cycle analysis using propidium iodide (PI) stain and in 
vivo anticancer efficacy in 1,2-dimethyl hydrazine (DMH) induced colorectal carcinoma in Wistar rats. The com-
pounds induced apoptosis in more than 30 % cells in AO/EB and Annexin V staining. They also showed cell cycle 
arrest in G2/M phase with PI staining. They showed a significant reduction in aberrant crypt foci formation and 
adenocarcinoma count along with a significant (p<0.05) reduction in TNF-α levels as compared to DMH control 
at 100 mg/kg dose. Thus, it can be concluded that the synthesized 2′-hydroxychalcones were effective against 
colon adenocarcinoma in in vitro and in vivo studies. 
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INTRODUCTION 
Cancer is a multifactorial disease charac-
terized by uncontrolled and abnormal cellular 
growth. Unlike normal cells, cancer cells con-
tinue to grow and divide eventually replicat-
ing exponentially into harmful cells (Pisani et 
al., 1999). It is undoubtedly a life threatening 
disease. However, there is a misconception 
about its cure. Much of the efforts in cancer 
research carried out during the last few dec-
ades prompted the researchers and cell biolo-
gist in understanding its pathophysiology, sig-
naling mechanism and developing strategic 
therapies that can effectively treat cancer so 
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as to eliminate or slow the impact of disease 
on patients’ lives. The 5-year relative survival 
rate for all cancers diagnosed in 2004-2010 
was 68 %, up from 49 % in 1975-1977 (Siegel 
et al., 2015). 
Among the various types of cancer diag-
nosed, it is worth mentioning that colorectal 
cancer (CRC) is the third most fatal malig-
nancy affecting both men and women (Siegel 
et al., 2014). Most CRC develops slowly as 
non-cancerous polyp (adenomas) and show 
harmful effects over years evolving into inva-
sive cancer (Schulmann et al., 2002). Several 
risk factors including age, familial history of 
adenomatous polyps, diet and heavy alcohol 
consumption have been implicated in the 
pathogenesis of CRC (Haggar and Boushey, 
2009). Apart from these factors, recent re-
search has also highlighted the role of epige-
netics in CRC (Goel and Boland, 2012). 
Among the epigenetic factors, histone 
deacetylases (HDACs) a group of enzymes 
involved in silencing gene expression are re-
ported to be over-expressed in CRC 
(Mariadason, 2008). Amid the various modal-
ities of treatment strategies available for 
CRC, surgery is the most preferred choice de-
pending on the stage of CRC. However, a per-
son’s general health plays a crucial role for 
better outcome of surgery. Furthermore, sur-
gery along with chemotherapy is recom-
mended in many cases for long term survival 
and prevention of reoccurrence (Giacchetti et 
al., 1999). Although there are many chemo-
therapeutic drugs for CRC, side effects asso-
ciated with them limits their usage, providing 
researchers to develop newer molecules lead-
ing to better therapeutic outcome. 
The current drug discovery program has 
explored natural products such as bio flavo-
noids, polyphenols, chalcones for their anti-
oxidant and cytotoxic properties that have 
given insight to the medicinal chemists to use 
them as potential anti-cancer agents. Chal-
cones are precursors of flavonoids that are 
present in various parts of a plant having anti-
inflammatory and anti-tumor activity (Jeon et 
al., 2012; Zhang et al., 2013). It is noteworthy 
to mention that quercetin, a cyclized chalcone 
and curcumin have been explored as potential 
anti-cancer agents. However, a few detailed 
studies have been carried out on the anti-tu-
mor properties of chalcones against colon ad-
enocarcinoma. They are considered to have 
fewer side effects when compared with 
chemotherapeutic agents (Syam et al., 2012). 
In addition, there is an increasing arousal of 
interest in flavonols and other dietary poly 
phenols owing to their HDAC inhibitory ac-
tivity in cancer cells (Rajendran et al., 2011). 
Thus, chalcones and flavonols could be most 
appropriate candidates to be evaluated for 
their HDAC inhibitory potential. Hence, our 
study was aimed at developing different sub-
stituted chalcones and assessing their anti-
cancer activity against colon adenocarci-
noma.  
 
MATERIALS AND METHODS 
Chemicals and instruments 
Chemicals used for synthesis were pro-
cured from Sigma-Aldrich Co. LLC, St. 
Louis, MO, USA; Merck Specialities Pvt. 
Ltd, Mumbai, India; Spectrochem Pvt. Ltd., 
Mumbai, MH, India. Melting point of the syn-
thesized compounds were determined using 
capillary melting point apparatus from Tosh-
niwal Systems and Instruments Pvt. Ltd., 
Chennai, TN, India. Thin layer chromatog-
raphy was carried out on pre-coated silica gel 
plates procured from Merck # 60F254 using 
the following developing system: Hexane/ 
Ethyl acetate (8:2, v/v) and the spots were vis-
ualized under UV lamp (254 or 366 nm) 
and/or iodine vapor. The IR spectra were rec-
orded using IR spectrometer (Model FTIR-
8300, Shimadzu Co., Kyoto, Japan) using 
KBr pellets. Mass spectra were recorded us-
ing LC-MS (ESI) (Model LCMS-2010A, Shi-
madzu Co., Kyoto, Japan). 1H and 13C NMR 
were recorded at 400 MHz (Model Ascend 
400, Bruker Biosciences Corporation, Biller-
ica, MA, USA) using DMSO (D6) as solvent. 
Chemical shifts are reported in δ values 
(ppm). Signal multiplicities are represented 
by s (singlet), d (doublet), m (multiplet). All 
tested compounds possess a purity of not less 
than 95 %.  
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Synthesis 
Compounds were synthesized by Claisen-
Schmidt condensation reaction. To a solution 
of substituted 2-hydroxyacetophenone (5 
mM) in 15 ml of ethanol, 5 ml of 20 % aque-
ous potassium hydroxide was added. After 
stirring the reaction mixture for 30 minutes, 
substituted benzaldehyde (5 mM) was added 
in portions. Stirring was continued for a pe-
riod of 10 h or more till the completion of re-
action. The progress of the reaction was mon-
itored by TLC using n-hexane and 
ethylacetate (8:2). The mixture was then sus-
pended in ice cold water and the resulting so-
lution was acidified with dilute hydrochloric 
acid. The precipitated product was collected 
by filtration and washed with ice cold water 
to remove any colored impurities and dried. It 
was crystallized using ethanol (Ameta et al., 
2011). The synthesis scheme is shown in Fig-
ure 1. 
 
Figure 1: Synthetic scheme of chalcones. 
Synthesis of chalcones was carried out using ace-
tophenone (A) and benzaldehyde (B) where 2ʹ-
hydroxy acetophenone was used for the prepara-
tion of C1-C4, 2,4-dihydroxy acetophenone for C5 
and 2,6-dihydroxy acetophenone for C6. Benzal-
dehyde used were 4-methyl benzaldehyde for C1, 
4-hydroxy benzaldehyde for C2, 4-carboxy ben-
zaldehyde for C3 and C6 and 4-(dimethyla-
mino)benzaldehyde for C4 and C5. The reaction 
conditions were (a) 20 % w/v potassium hydrox-
ide, ethanol and stirring at room temperature for 
12-16 h.  
Physiochemical and spectral data of the  
synthesized substituted chalcones 
C1: 1-(2-Hydroxy-phenyl)-3-p-tolyl-prope-
none  
Yield = 80 %, m.p. 168 ± 2 °C uncor-
rected; IR (KBr); 3444.98 (-OH, Str), 1639 
(C=O, Str), 2918 (Ar, C-H) cm-1; 1H NMR 
(400 MHz, DMSO (D6)) δ 12.56 (1H, s), 8.25 
(1H, d), 8.013 (1H, d) 7.845-7.55 (4H, m), 
7.31-6.99 (4H, m), 2.36 (3H, d) ppm; 13C 
NMR (400 MHz, DMSO (D6)) δ 194.14 
(C=O), 162.08 (C-OH), 145.44 (C=C-C), 
143.0 (C-CH3), 141.67-118.20 (10C-C), 
21.60 (C-C-H) ppm. MS (ESI): m/z (M+1) 
239.17  
C2: 3-(4-Hydroxy-phenyl)-1-(2-hydroxy-phe-
nyl)-propenone  
Yield = 75 %, m.p. 172 ± 2 °C uncor-
rected; IR (KBr); 3441.12(-OH, Str), 1633.76 
(C=O, Str), 1082 (C-O, Str) cm-1; 1H NMR 
(400 MHz, DMSO (D6)) δ 14.63 (1H, s), 
9.626 (1H, s), 7.798 (1H, d), 7.591 (1H, d), 
7.358-6.816 (6H, m), 5.566 (2H, d) ppm; 13C 
NMR (400 MHz, DMSO (D6)) δ 192.45 
(C=O), 158.17 (OH-C=C), 136.68 (C=C-
OH), 129.56 (C-C=C), 128.80-115.63 (11 C-
C) ppm. MS (ESI): m/z (M+1) 241.0 
C3: 4-[3-(2-Hydroxy-phenyl)-3-oxo-pro-
penyl]-benzoic acid  
Yield = 96 %, m.p. 180 ± 2 °C uncor-
rected; IR (KBr); 3433 (-OH, Str), 1633 
(C=O, Str), 1766 (Ar COOH, C=O Str), 
2924.18 (COOH, O-H Str) cm-1;  1H NMR 
(400 MHz, DMSO (D6)) δ 12.35 (1H, s), 
11.53 (1H, s), 7.822 (1H, d), 7.862 (1H, d), 
7.821-7.513 (4H, m), 7.008 -6.117 (4H, m) 
ppm; 13C NMR (400 MHz, DMSO (D6)) δ 
201.45 (C=O), 170.18 (OH-C=O), 162.10 (C-
C=C), 136.66-118.14 (12C-C) ppm. MS 
(ESI): m/z (M+1) 269.08 
C4: 3-(4-Dimethylamino-phenyl)-1-(2-hy-
droxy-phenyl)-propenone 
Yield = 75 %, m.p. 178 ± 2 °C uncor-
rected; IR (KBr); 3448 (-OH, Str), 1604 
(C=O, Str), 1377 .22 (CH3) 
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C5: 1-(2-Hydroxy-4-methyl-phenyl)-3-p-
tolyl-propenone 
Yield = 80 %, m.p. 153 ± 2 °C uncorrected; 
IR (KBr); 3443.05 (-OH, Str), 1597 (C=O, 
Str) 
C6: 4-[3-(2,6-Dihydroxy-phenyl)-3-oxo-pro-
penyl]-benzoic acid  
Yield = 65 %, m.p. 186 ± 2 °C uncor-
rected; IR (KBr); 3070.78 (-OH, Str), 1616.40 
(C=O, Str), 1707.06 (Ar COOH, C=O Str), 
2652.21 (COOH, O-H Str). 
 
In vitro studies  
Cell lines and their maintenance  
Human colorectal carcinoma (HCT116) 
and African green monkey kidney epithelial 
cells (VERO) were procured from the Na-
tional Centre for Cell Science, Pune, MH, In-
dia. The cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-
Aldrich Co. LLC, ST. Louis, Mo, USA) sup-
plemented with 10 % Fetal Bovine Serum 
(FBS) (HiMedia Laboratories, Mumbai, In-
dia) and 1 × Penicillin/Streptomycin at 37 °C 
in CO2 incubator (NU-5501 E/G, NuAire Inc., 
Plymoth, MN, USA) in humidified atmos-
phere of 5 % CO2 and 95 % air. The cells were 
maintained by routine sub-culturing in 25 cm2 
tissue culture flasks.  
Cytotoxicity assay  
Cytotoxic potential of the test compounds 
were assessed using MTT assay (Kumar et al., 
2016). In brief, HCT116 and Vero cells were 
harvested from confluent flask and seeded (5 
× 104 cells/well) in 96 well plates. After 24 h 
of incubation, the cells were exposed to dif-
ferent concentration of the test compounds for 
48 h. Further, 50 µl of MTT reagent (HiMedia 
Laboratories, Mumbai, India) (2 mg/ml in 
sterile PBS) was added into each well after 48 
h and incubated for 3 more h. The formazan 
crystals formed were solubilized using 100 % 
DMSO and the optical density was measured 
at 540 nm using micro plate reader (ELx800, 
BioTek Instruments Inc., Winooski, VT, 
USA).  
Whole cell HDAC enzyme assay 
HCT116 cells were harvested and seeded 
in 96 well sterile, black well plates at 2 × 104 
cells/well and incubated overnight. Further, 
the cells were treated with different concen-
tration of the test compounds for a period of 
18 h. Then, 15 mM Boc-Lys(Ac)-AMC sub-
strate (Sigma Aldrich # SCP0168) was added 
and incubated for 1 h. The reaction was termi-
nated by the addition of 50 µL of stop solution 
(trypsin 2 mg/ml, 1 % NP40, 1 µl SAHA) in 
HDAC assay buffer (25 mM Tris-HCl (pH 
8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM 
MgCl2). The reaction was then allowed to 
proceed for 15 min at 37 °C after which, the 
fluorescence was measured at 360 nm excita-
tion and 460 nm emission using fluorescence 
micro plate reader (FLx800, BioTek Instru-
ments Inc., Winooski, VT, USA) (Reddy et 
al., 2015). 
Acridine orange/Ethidium bromide (AO/EB) 
staining 
AO/EB dual staining was performed in or-
der to determine the apoptosis inducing po-
tential of the selected test compounds in 
HCT116 cell line with few modifications 
(Kumar et al., 2016). In brief, 5 × 105 cells 
were seeded in 6 wells plate containing 2 ml 
of medium and incubated for 24 h. After 24 h, 
cells were treated with the test compounds 
and incubated for 48 h. After 48 h of incuba-
tion, the wells were washed with phosphate 
buffer saline (PBS) and cells were fixed with 
ice cold ethanol (70 %) for 30 min. Ethanol 
was then removed and cells were washed 
again with PBS followed by the addition of 
200 µl of AO/EB (20/30 µg/ml) stain in each 
well. The plate was later kept in the dark for 
20 min. The excess stain was further washed 
thrice with PBS and observed for their fluo-
rescence under a fluorescent microscope 
(Eclipse TS100-F, Nikon Instruments Inc., 
Melville, NY, USA). 
Annexin V assay 
Apoptosis determination by Annexin V 
staining was carried out using Muse Cell An-
alyzer with the kit provided by the manufac-
turer Merck Millipore. In brief, 1 × 106 cells 
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were seeded in 60 mm tissue culture dish and 
after overnight adherence test compounds 
were added and incubated. After 48 h the cells 
were detached by trypsinization, centrifuged 
and resuspended. 100 µl of cell suspension 
was added with 100 µl of Annexin V reagent 
and incubated for 20 min at room temperature 
following which the cells were analyzed for 
apoptosis. 
 
Cell cycle analysis 
The ability of the test compounds to arrest 
any phase of the cell cycle was determined us-
ing the described procedure (Reddy et al., 
2015). In this method, HCT116 cells were 
harvested and seeded at a density of 1 × 106 
cell in 60 mm petri plate and incubated for 24 
h. After 24 h cells were treated with test com-
pounds for 48 h. Then the cells were washed 
with PBS, trypsinized and centrifuged. The 
cell pellets were later fixed in 70 % ice cold 
ethanol and stored at -20 °C for 24 h. After 
fixing, the pellet was dislodged in PBS and 
stained with propidium iodide solution. The 
cells were then analyzed using Accuri C6 
flow cytometer with the threshold levels ad-
justed to remove the debris (BD Biosciences, 
San Jose, CA, USA)  and data analysis were 
performed  using BD Accuri™ C6 software.  
 
In vivo studies 
Animals 
Male Wistar rats inbred at the Central An-
imal Research Facility, Manipal University, 
were used in our study. The animal care and 
handling were carried out in accordance with 
the guidelines issued by the Institutional Ani-
mal Ethics Committee (IAEC), Manipal. Af-
ter obtaining research proposal approval 
(IAEC/KMC/16/2015) the animals were ac-
climatized to the experimental room having 
temperature of 23 ± 2 °C, humidity (50 ± 5 %) 
and 12 h light and dark cycles. Rats were 
housed in sterile polypropylene cages con-
taining sterile paddy.  
Acute toxicity studies  
Acute toxicity study was carried out to de-
termine the safe dose using Organization for 
Economic Cooperation and Development 
(OECD) – 425 guideline. Limit test was per-
formed using 2000 mg/kg dose of the test 
compounds in 6 h fasted rats. Animals were 
observed for any signs of toxicity for the first 
4 h continuously and then daily for 14 days.  
 
Preparation of the test compound and  
standard drug 
Test compound: Three test compounds, 
namely C1, C2 & C3 were suspended in 
0.25 % sodium carboxy methyl cellulose 
(CMC) and were administered orally (p.o) 
with a dosing volume of 10 ml/kg.  
Standard drug: 5-Fluorouracil (5-FU) was 
used as standard. It was procured in the form 
of injection and administered intraperitone-
ally (i.p) with a dosing volume of 10 ml/kg. 
 
DMH (1,2-dimethyl hydrazine) induced  
colon cancer in Wistar rats 
Induction of colon cancer was achieved 
using DMH according to a previously de-
scribed procedure with few modifications 
(Perše and Cerar, 2005). DMH at a dose of 
30 mg/kg was administered i.p once a week 
for 20 weeks. The incidence of aberrant crypt 
foci (ACFs) and adenocarcinoma were con-
firmed by sacrificing a few of the animals af-
ter 20 weeks confirming the induction of co-
lon cancer in experimental animals. Finally, 
the animals were randomized into five exper-
imental groups based on their body weight.  
Experimental groups 
Group 1 (normal control): Animals (n=6) 
were administered 0.25 % CMC in water p.o. 
Group 2 (DMH control): Animals (n=6) were 
administered DMH 
Group 3 (standard drug): Animals (n=6) re-
ceived 5-FU 10 mg/kg i.p. for 21 days of 
study period 
Group 4 (C1): Animals (n=6) received C1 at 
100 mg/kg p.o for 21 days 
Group 5 (C2): Animals (n=6) received C2 at 
100 mg/kg p.o. for 21 days.  
Group 6 (C3): Animals (n=6) received C3 at 
100 mg/kg p.o. for 21 days.  
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Parameters assessed in the experimental 
animals 
ACF formation and adenocarcinoma  
incidence 
The distal part of the colon, which was re-
moved from the experimental animals after 
the study period was cut open and placed flat 
on a filter paper and fixed with 10 % buffered 
formalin for 12 h. Further, it was stained with 
0.1 % methylene blue in PBS for 5 min. Spec-
imens were later observed under microscope 
for ACF formation and  were calculated as the 
number of counts/5 cm2 in colon tissue. The 
entire colon was considered to study the inci-
dence of adenocarcinoma. The growth was 
critically observed and the count and size 
were noted from each animal.  
TNF-α level 
The levels of TNF-α were estimated in the 
colon of experimental animals, for which 
10 % homogenate of colon tissue was pre-
pared in tissue lysis buffer. The homogenate 
was centrifuged and the supernatant was col-
lected to measure TNF-α levels using com-
mercially available ELISA kits of rat TNF-α 
(# KRC3011, Invitrogen). 
Colon length/weight ratio and organ index 
Length of the isolated colon was meas-
ured in centimeters and weight was measured 
in g. The colon length/weight (L/W) ratio was 
then calculated. Isolated spleen, kidney and 
heart of the experimental animals were also 
weighed in g and respective index was calcu-
lated. 
Histopathology of colon 
Histopathology was carried out according 
to the described procedure (Reddy et al., 
2015). The stained slides were then analyzed 
under a microscope for any anatomical 
changes.  
Statistical analysis 
All the values were expressed as mean ± 
SEM of 6 animals. Data were analyzed using 
one-way ANOVA followed by Tukey’s mul-
tiple comparison tests using Prism 5.03 
(Graph Pad Software Inc., La Jolla, CA, 
USA). Values of p < 0.05 were considered to 
be significant.  
 
RESULTS 
In vitro studies 
MTT assay 
MTT assay was carried out to evaluate the 
cytotoxic potential of the synthesized com-
pounds on HCT116 and Vero cell line. Com-
pounds C1, C2, C3 and C5 were found to be 
cytotoxic against colon cancer cell line after 
48 h of treatment. Among these compounds, 
C1 was found to be most cytotoxic with an 
IC50 value of 37.07 µM on HCT116 cells. Fur-
thermore, in Vero cell lines C1, C2 and C3 
exhibited potential cytotoxicity compared 
with the remaining three synthesized com-
pounds. Moreover C1 displayed greater cyto-
toxicity compared with C2 and C3. Table 1 
provides the IC50 value of the synthesized 
compounds on both the cell lines tested.  
 
 
Table 1: In vitro cytotoxicity screening in human 
colon cancer and normal cells  
COMPOUND IC50 Value (µM/ml) 
HCT116 VERO 
C1 37.07 26.28 
C2 81.41 88.26 
C3 116.9 177.8 
C4 >500 >500 
C5 261.2 >500 
C6 >500 >500 
The IC50 values were calculated using nonlinear regression 
analysis. All values are represented as mean of the experi-
ments carried out in triplicate.  
 
Whole cell HDAC assay 
The whole cell HDAC enzyme inhibition 
assay was performed to determine the effect 
of test compounds on the epigenetic machin-
ery of HCT116 cells. Dose dependent HDAC 
enzyme inhibition was observed in all treat-
ment groups, with C1 as the most potent com-
pound with an IC50 value of 105 ± 10 µM. The 
other potent compound was found to be C5 
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with IC50 value below 200 µM i.e, 160.4 ± 
15.5 µM. The IC50 values for the remaining 
compounds were 394.3 ± 12.9, 928.7 ± 56.6, 
470.4 ± 11 and 826.1 ± 58.1 µM respectively 
for C2, C3, C4 and C6. SAHA, a non-specific 
HDAC inhibitor, was used as standard and 
was found to have an IC50 value of 3.6 ± 
0.2 µM. Figure 2 shows the histogram plot of 
whole cell HDAC assay. 
AO/EB staining 
To determine the mechanism of cell death 
induced by test compounds, fluorescent dye 
based apoptosis assay was carried out. In the 
present study Acridine Orange/Ethidium Bro-
mide stain was used. Green stained unfrag-
mented nuclei were observed in untreated 
cells, indicating non-apoptotic cells. Where-
as, the presence of highly condensed chromo-
some was visible in cells treated with test 
compounds appearing as green fragmented 
nuclei. Treatment with 5-FU showed 45 ± 
0.87 % apoptotic cells in HCT116 cells. Al-
ternatively, % apoptotic cells in C1, C2 and 
C3 treated groups were found to be 42.4 ± 
2.25 %, 40 ± 2.5 % and 38.7 ± 0.94 % respec-
tively. Figure 3 shows the % apoptotic cells 
represented as histogram and Figure 4 shows 
the fluorescent images.  
  
 
Figure 2: Whole cell HDAC inhibition assay. 
The histogram plot represents the IC50 value of whole cell HDAC enzyme inhibition assay carried out in 
HCT116 cell line. All values are represented as mean ± SEM and the experiments were carried out in 
triplicate.  
 
Figure 3: Percentage apoptotic cells in HCT116 cell line. 
Percentage apoptotic cells in HCT116 cell line determined by AO/EB staining. All values are mean ± 
SEM of 100 cells. ap< 0.05 vs. control.  
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Figure 4: AO/EB staining in HCT116 cell line. 
The images indicate induction of apoptosis in HCT116 cell line by various treatment groups after 48 hrs. 
(A) Normal control, (B) 5-FU, (C) C1, (D) C2, (E) C3. Arrows indicate condensed nucleus. Magnification 
40X. 
 
 
 
Apoptosis detection study 
During apoptosis, phosphatidylserine 
which is predominantly situated along the cy-
tosolic side of the plasma membrane translo-
cates to the extracellular side. After transloca-
tion, it is detectable by the family of calcium-
dependent phospholipid binding proteins 
called Annexin. More than 30 % of apoptotic 
cells were observed after 48h of incubation in 
the various treatment groups. Total apoptotic 
cells in normal, 5-FU, C1, C2 and C3 was 
found to be 6.10 %, 38.08 %, 37.70 %, 
36.60 %, and 31.80 % of total cells respec-
tively. Early apoptotic events were more 
prominent in the treatment of 5-FU and C2 
with 15.86 % and 18 % of total cells, respec-
tively, while it was less in C1 and C4 treat-
ment 5.85 % and 4.55 %, respectively (Figure 
5). 
Cell cycle analysis 
Cell cycle analysis revealed that cells in 
normal control contained 72.5 %, 9.5 % and 
18.2 % cells in G0/G1, S and G2/M phase re-
spectively. The treatments with C1 and C2 
showed a notable cell cycle arrest in G2/M 
phase by increasing the percentage cell counts 
compared to normal control i.e., 25 % and 
19.5 % cells respectively. These results sug-
gested potentials of C1 and C2 as a G2/M 
phase blocker. Furthermore an increase in the 
percentage of cells in S phase (12 %) was ob-
served in C3 treatment compared to normal 
control (Figure 6). 
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Figure 5: Determination of apoptosis by Annexin V staining. 
Effect of binding of Annexin V on the surface of HCT116 cell after 48 hrs of treatment. Apoptosis was 
determined as % live, early and late apoptosis/dead cells by MUSE cell analyzer.  
 
 
In vivo studies 
In vivo toxicity studies 
No signs of toxicity were observed in the 
experimental animals treated with the test 
compounds at 2000 mg/kg dose. Further stud-
ies were carried out using 1/20th of the admin-
istered dose.  
 
DMH (1,2-dimethyl hydrazine) induced  
colon cancer in Wistar rats  
 
ACF formation and adenocarcinoma  
incidence 
The incidence of colon carcinoma is com-
monly detected with the presence of aberrant 
crypt foci and the incidence of adenocarci-
noma. The ACF formation in the DMH 
treated control group were 81.6 ± 1.4/5 cm2 of 
colon tissue, whereas no such incidences were 
observed in normal control group. The ACF 
count was found to be significantly (p<0.05) 
lower in the all treatment groups compared to 
DMH control (Table 2).  
Adenocarcinoma formation was observed 
in the entire colon region of DMH treated 
control group (15 ± 1.2). Treatment with 5-
FU and C1 showed significant decrease in the 
number of adenocarcinoma compared to 
DMH control group (7 ± 0.5 and 10 ± 0.8 re-
spectively). However no significant decrease 
in adenocarcinoma was observed in C2 and 
C3 treatment compared to DMH control 
group (Table 2). 
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Figure 6: Cell cycle analysis in HCT116 cell line. 
Effect on the cell cycle of HCT116 cells after 48 hrs of treatment. Histogram showing various phases of 
the cell cycle where M1 represent G0/G1 phase, M2 represent S phase and M3 represent G2/M phase. 
(A) Normal control, (B) Doxorubicin, (C) C1, (D) C2, (E) C3 
 
 
Table 2: Effect of DMH and test compounds on ACF and adenocarcinoma count 
Group No. of ACF/5 cm2 No. of adenocarcinoma 
Normal control 0 0 
DMH control 81.6 ± 1.4# 15 ± 1.2# 
5-FU 42.3 ± 1.4* 7 ± 0.5*
C1 54.0 ± 0.5* 10 ± 0.8*
C2 60.0 ± 1.1* 13 ± 1.1ns
C3 73.6 ± 0.8* 12 ± 1.09ns
All values are expressed as mean ± SEM of 6 animals, where #p<0.05 compared to Normal control, *p < 0.05 vs. DMH control,  
ns - no significant difference compared to DMH control. 
 
 
 
TNF-α level in colon homogenate 
A significant (p<0.05) increase in the lev-
els of TNF-α was observed in DMH control 
group (20.2 ± 0.8) compared to normal con-
trol (0.8 ± 0.1) group, suggesting an increase 
in inflammation. 5-FU treatment (16.09 ± 1.9) 
was able to reverse the increased TNF-α lev-
els in the colon homogenate when compared 
with the DMH control group. Treatment with 
all test compounds showed significant 
(p<0.05) reversal in the increased TNF-α lev-
els compared to DMH control group. Among 
the tested compounds, the maximum reversal 
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in TNF- α levels was observed in C1 treated 
group (6.18 ± 2.5), which was found to be sig-
nificant compared to DMH control group and 
5-FU group (Figure 7). 
Colon length/weight ratio and organ index 
Formation of adenomas or polyps in the 
colon causes a decrease in the length of colon 
with an increase in its weight. We observed a 
significant (p<0.05) increase in colon 
length/weight ratio in the DMH control group 
compared with that of normal control group. 
No significant (p<0.05) decrease in length/ 
weight ratio was observed by the treatment 
with 5-FU and C3 compared to DMH control 
group. However, treatment with C1 and C2 
significantly lowered the Colon L/W ratio 
compared to DMH control group (Table 3). 
There were no significant alterations in vari-
ous organ indices in the treatment groups 
compared to DMH and normal control (Table 
4).  
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Figure 7: Effect of various treatments on TNF-α levels. 
Effect of DMH administration for 21 days on the inflammatory marker TNF-α in colon tissue homogenate. 
All values are mean ± SEM of 6 animals. ap<0.05 vs. Normal control, bp<0.05 vs. DMH control, cp<0.05 
vs. 5-FU.  
 
 
Table 3: Effect of various treatments on colon L/W ratio 
SL. No. Group Colon L/W ratio (cm/g) 
1 Normal control 10.8 ± 0.06 
2 DMH control 12.6 ± 0.09* 
3 5-FU 10.8 ± 0.05* 
4 C1 9.7 ± 0.02*# 
5 C2 10.1 ± 0.04*# 
6 C3 10.9 ± 0.08 
All values are expressed as mean ± SEM of 6 animals. *p< 0.05 vs. normal control, #p< 0.05 vs. DMH control. L/W represent 
Length/Weight ratio. 
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Table 4: Effect of test compounds on organ index  
Group Spleen index Kidney index Heart index 
Normal control 0.3 ± 0.04 0.6 ± 0.03 0.3 ± 0.01 
DMH control 0.3 ± 0.02ns 0.6 ± 0.02ns 0.3 ± 0.01ns 
5-FU 0.4 ± 0.02ns 0.7 ± 0.02ns 0.2 ± 0.01ns 
C1 0.4 ± 0.01ns 0.76 ± 0.02ns 0.3 ± 0.1ns 
C2 0.4 ± 0.01ns 0.6 ± 0.02ns 0.3 ± 0.0ns 
C3 0.4 ± 0.01ns 0.7 ± 0.03ns 0.3 ± 0.01ns 
All values are expressed as mean ± SEM of six animals. ns - no significant difference between normal control. 
 
 
 
Histopathology of colon 
Observation of the section of colon in the 
normal control group displayed a normal ar-
chitecture with finger like mucosal projec-
tions called villi and the presence of crypts in 
between them. No sign of dysplasia or crypt 
abscess was observed in the normal control 
group. However, sections of colon in DMH 
control group had a distorted morphology 
with the formation of crypt abscess and aber-
rant crypt foci. Treatment with various com-
pounds showed a restoration in the morphol-
ogy of the colon along with a reduction in the 
formation of crypt abscess (Figure 8).
 
 
 
Figure 8: Effect of test compounds on the histopathology of colon. 
Photomicrographs of histological changes in the colon of experimental animals at 400 x magnification. 
(A) Normal Control, (B) DMH control, (C) 5-FU, (D) C1, (E) C2, (F) C3. The arrows indicate aberrant 
crypt foci.  
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DISCUSSION 
In the present study, six substituted 2′hy-
droxy chalcones were synthesized and their 
anticancer potential was evaluated using in 
vitro mechanistic and target specific studies in 
human colon cancer cell line. Furthermore, 
the efficacy of the test compounds was as-
sessed in in vivo model of colon adenocarci-
noma. Since, various factors (including genet-
ics, epigenetics and environmental) are in-
volved in understanding the pathophysiology 
of cancer, it is regarded as a multifactorial dis-
ease (Liu et al., 2008). Several targets are val-
idated among these factors which play a criti-
cal role in this complex disease. HDACs, a 
group of enzymes, are involved in altering tu-
mor suppressor gene expression and regulat-
ing the stages of apoptosis and cell cycle pro-
gression (Minucci and Pelicci, 2006). Numer-
ous studies have demonstrated the increased 
expression of HDAC in colon cancer 
(Nakagawa et al., 2007), based on which we 
explored the ability of the synthesized com-
pounds to inhibit this target. 
Cytotoxicity assays are frequently used to 
screen various compounds for their ability to 
inhibit cell proliferation and viability. One co-
lon cancer cell line, namely HCT116 and one 
normal cell line, i.e., Vero cells were used to 
evaluate the cytotoxic potential of these syn-
thesized compounds. On HCT 116, C1, C2, 
C3 showed IC50 values below 200 µM. Ex-
cept C5, none of the tested compounds 
showed selective cytotoxicity to cancer cells.  
Further HDAC inhibition study was per-
formed for all the synthesized compounds to 
evaluate their potential to modulate the epige-
netic pathways leading to the expression of 
apoptosis inducing genes. It is well docu-
mented that cancer development is not limited 
to genetic changes rather it involves interplay 
between genetic and epigenetic regulation 
(You and Jones, 2012). The insight on the ep-
igenetic regulation provides a platform to un-
derstand the rationale for the development of 
drug candidates that could target the epige-
nome of a cell. Further, the chances of inter-
action between histone and DNA increases 
owing to the deacetylation of histone resulting 
in chromatin compaction and repression of 
genes involved in apoptosis and cell cycle 
progression (Ropero and Esteller, 2007). 
Moreover, an imbalance between the enzyme 
histone acetyltransferases (HAT) and histone 
deacetylases (HDAC) is observed in cancer 
with the balance shifting towards HDAC over 
activity. Thus, the present study was designed 
to identify the dose dependent inhibitory re-
sponse of the synthesized test compounds on 
HDAC enzymes. Four compounds namely 
C1, C2, C4 and C5 showed inhibition of 
HDAC with IC50 value below 500. Thus tak-
ing mainly cytotoxicity data into considera-
tion along with HDAC inhibition data three 
molecules were selected for further evalua-
tion of their mechanistic and efficacy study. 
Attempts were made to understand the 
Structure Activity Relationship (SAR) of the 
chalcones synthesized. Although we could 
not clearly arrive at the SAR of the synthe-
sized compounds, some deductions from the 
structural modifications that might have di-
rectly or indirectly contributed for eliciting 
the anti-cancer activity could be drawn. Out 
of the six test compounds synthesized and 
screened for cytotoxicity compounds C1, C2 
and C3 with 2ʹ-hydroxy group and methyl, 
hydroxyl and carboxy substitution at the 4th 
position of the B ring, respectively, were 
found to exhibit anti-cancer potential at an 
IC50 value of less than 200 µM when com-
pared with the other synthesized compounds. 
The 2ʹ-hydroxyl group seems to have played 
a significant role in establishing the structural 
activity of chalcones with respect to mostly 
stabilizing them by forming hydrogen bond. 
Further, the 2ʹ-hydroxy group might also play 
a crucial role in chalcone-flavonone equilib-
rium (Avila et al., 2008). For this reason, the 
2ʹ-hydroxy group might be considered as an 
important functional group contributing to-
wards the activity. 
 Many reports available on chalcones 
showing anti-cancer potential bears a substi-
tution at the para position on the phenyl ring. 
Thus, the position 4 of B-ring plays an im-
portant role in determining the anti-cancer ac-
tivity. In our study, we observed that when 
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para position is substituted with methyl, hy-
droxyl and carboxyl group, the chalcones 
have shown promising anticancer activity. 
However, substitution with other group such 
as para dimethylamino leads to less active 
compounds. 
Further substitution bearing additional hy-
droxyl group at 4ʹ and 6ʹ position of A ring 
along with para dimethylamino and carboxyl 
substituent at the 4th position of the B ring 
seems to have generated compounds with 
lower activity than when they were not sub-
stituted. The mechanism of cell death and the 
arrest of cell cycle are the important parame-
ter for assessing anticancer potential of any 
drug. Thus, we examined the nature of the cell 
death induced by them using dual staining. 
AO/EB staining showed a significant change 
in nucleomorphological changes compared to 
the control cells. These changes were repre-
sented in the form of increase in apoptotic in-
dex. To further confirm these visual changes, 
the flow cytometry study was performed us-
ing Annexin V stain, which reflected two dis-
tinct ways through which cells probably die: 
apoptotic and necrotic pathways. Most of the 
potential anticancer drugs would kill cells by 
inducing apoptosis (Kaufmann and Vaux, 
2003). All three tested compound showed 
more than 30 % cells underwent apoptotic 
changes in cells which were significantly 
higher than the normal control, indicating that 
the nature of cell death was mediated by apop-
totic pathway.  
Cell cycle analysis was based upon the 
DNA content of a cell through flow cytome-
ter, where cells in various phases (G0/G1, S 
and G2/M) of the cell cycle were estimated. 
Further, we could assess whether the test 
compounds were cell cycle specific inhibitors 
or not. G1 is the initial phase of the cell cycle 
where, DNA damage would terminate the 
progression of the cell cycle and allows repair 
to take place before cell would enter the S 
phase. In the event of unsuccessful repair, ac-
cumulation of phosphorylated p53 initiates 
for the programmed cell death (Nowsheen 
and Yang, 2012). Our results suggested that 
the test compounds were able to induce apop-
tosis and inhibit cell division mostly by arrest-
ing G0/G1 phase of the cell cycle.  
Further, development of colorectal cancer 
in rodents was observed using DMH, a highly 
specific colorectal carcinogen. DMH and its 
metabolite azoxymethane (AOM) promotes 
the initiation and advancement of colorectal 
carcinogenesis in rodents. Aberrant crypt foci 
are the first identifiable colonic lesions. A 
similar observation was found in our study 
confirming the induction of colorectal carci-
noma in experimental animals. Literature sug-
gests that, the reduction in ACF is a marker of 
recovery from colorectal carcinoma (Davis 
and Iwahashi, 2001). Our results demon-
strated that the test compounds were able to 
reduce ACF formation significantly when 
compared to DMH control suggesting their 
preventive role. Alternatively, a reduction in 
the number of colon adenocarcinoma in the 
treatment groups further supported their ef-
fectiveness. Colonic edema due to tissue in-
jury or inflammation could also cause a rise in 
colon weight/length ratio. Our treatment re-
duced the rise in colon weight/length ratio 
when compared with that of DMH control 
further suggesting their role in lowering the 
tissue injury or inflammation. This was fur-
ther supported by the estimation of TNF-α 
level in colonic homogenate. TNF-α is a well-
established marker for inflammatory pathway 
and their levels are increased in DMH ex-
posed rats (Umesalma and Sudhandiran, 
2010). Here, the test compounds were able to 
decrease TNF-α level in DMH treated rats, in-
dicating their ability to counteract inflamma-
tion arising from tissue injury. Histopatholog-
ical studies showed aberrant crypt foci for-
mation and mucosal enlargement in DMH 
treated group. Restoration in the morphology 
of colon was also evident in the treatment 
groups with reduction in mucosal enlarge-
ment and reduced ACF formation suggesting 
their protective effect.  
The present study was designed to evalu-
ate the protective effect of various substituted 
chalcones both in vitro and in vivo. In vitro 
studies proved the potential of the compounds 
EXCLI Journal 2017;16:448-463 – ISSN 1611-2156 
Received: September 15, 2016, accepted: March 13, 2017, published: April 03, 2017 
 
 
462 
to induce apoptosis and arrest G0/G1 phase of 
cell cycle in human colon cancer cell line. We 
also found that they were able to alter the ep-
igenetic pathways evident from HDAC inhi-
bition. In addition, we observed a reduction in 
ACF and adenocarcinoma formation in the 
colon of animals treated with the test com-
pounds. Furthermore, they were able to lower 
the increased levels of TNF-α suggesting their 
role in inflammation. These results demon-
strated the efficacy of the compounds against 
colon adenocarcinoma, providing a potential 
lead for anticancer drug development. 
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